Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery

Table 1

Characteristics of studies included in meta-analysis.

Author (year)	Study design	Study location	OVDs	N (eyes)	Mean age	Age (SD)
Arshinoff (1997) [11]	RCT	Canada	MicroVisc	51	70	10
	RCT	Canada	Healon	49	70	11
Arshinoff (1998) [4]	RCT	Canada	MicroVisc Plus	100	70	10
	RCT	Canada	Healon GV	100	66	10
Arshinoff (2002) [3]	RCT	Canada	Healon5	50	71.5	9.6
	RCT	Canada	Healon GV	99	71.7	9.6
	RCT	Canada	Healon	49	71.9	7.5
Auffarth (2017) [18]	RCT	Europe	Twinvisc	109	71.9	7.4
	RCT	Europe	DuoVisc	111	72.5	7.9
Behndig (2002) [19]	RCT	Sweden	Healon GV	21	72	10.4
	RCT	Sweden	Viscoat + Healon GV	20	72.8	11.7
	RCT	Sweden	Viscoat + Provisc	21	76.5	8.4
Chiselita (2008) [20]	RCT	Romania	Viscoat	44	68.8	9.8
	RCT	Romania	Provisc	52	68.8	9.8
Davis (2000) [2]	RCT	USA	Amvisc Plus	17	—	—
	RCT	USA	OcuCoat	17	—	—
	RCT	USA	Viscoat	16	—	—
Embriano (1989) [21]	RCT	USA	Sodium chondroitin sulfate-NaHa	50	—	—
	RCT	USA	NaHa	50	—	—
Espindola (2012) [22]	RCT	Brazil	DisCoVisc	39	71.5	7.9
	RCT	Brazil	2% HPMC	39	71.5	7.9
Holzer (2001) [1]	RCT	Germany	Healon GV	12	71.2	7.8
	RCT	Germany	Healon5	19	71.2	7.8
	RCT	Germany	Viscoat	20	71.2	7.8
	RCT	Germany	OcuCoat	15	71.2	7.8
	RCT	Germany	Celoftal	15	71.2	7.8
Hutz (1996) [23]	RCT	Germany	Methocel	50	—	—
	RCT	Germany	Viscoat	50	—	—
	RCT	Germany	Healon	50	—	—
	RCT	Germany	Healon GV	50	—	—
Kim (2004) [24]	RCT	Korea	Soft Shell (Viscoat + Hyal-2000)	69	64.15	12.92
	RCT	Korea	Viscoat	64	67.53	10.19
	RCT	Korea	Hyal-2000	64	63.22	11.51
	RCT	Korea	Provisc	55	63.3	12.78
Kocak-Altintas (2006) [25]	RCT	Turkey	BD Visc	83	65.6	11.1
	RCT	Turkey	Healon	83	65.8	11.3
Kohnen (1996) [12]	RCT	Germany	Healon	30	73.2	9.2
	RCT	Germany	Healon GV	30	73.2	9.2
Lee (2011) [26]	RCT	Korea	Amvisc Plus	31	65.42	12.20
	RCT	Korea	Balanced salt solution + Amvisc Plus	31	63.23	9.44
Miller (1999) [5]	RCT	USA	Healon GV	70	75.8	6.79
	RCT	USA	Viscoat	70	75.5	6.38
Miyata (2002a) [27]	RCT	Japan	Opegan	50	75.6	8.0
	RCT	Japan	Healon	28	74.3	8.7
Miyata (2002b) [28]	RCT	Japan	Soft Shell	37	74.8	10.2
	RCT	Japan	Healon	23	76.5	8.5
Moschos (2011) [13]	RCT	Greece	Viscoat	41	77.6	8.4
	RCT	Greece	Visthesia	36	77.7	8.7
Neumayer (2008) [29]	RCT	UK	Neocrom Cohesive	29	75	—
	RCT	UK	Healon	29	75	—
Oshika (2004) [30]	RCT	Japan	Healon5	79	69	10
	RCT	Japan	Healon	78	71	9
Oshika (2010) [6]	RCT	Japan	DisCoVisc	157	70.3	8.2
	RCT	Japan	Healon5	166	70.3	7.9
Ray-Chaudhary (2005) [31]	RCT	UK	Ophthalin	51	—	—
	RCT	UK	HPMC-Ophtal	50	—	—
Rainer (2000) [7]	RCT	Austria	Healon5	35	75.5	9.1
	RCT	Austria	Viscoat	35	75.5	9.1
Rainer (2001) [8]	RCT	Austria	OcuCoat	40	75.9	9.3
	RCT	Austria	Viscoat	40	75.9	9.3
Rainer (2007) [10]	RCT	Austria	NaHa 1%	40	75.1	8.0
	RCT	Austria	2% HPMC	40	75.1	8.0
Rainer (2008) [32]	RCT	Austria	Viscoat	30	76.6	7.4
	RCT	Austria	DuoVisc	30	76.6	7.4
Ravalico (1997) [33]	RCT	Italy	Healon	16	64.06	5.97
	RCT	Italy	Healon GV	15	61.64	9.56
	RCT	Italy	Viscoat	14	62.67	6.34
	RCT	Italy	Hymecel	13	62.85	7.55
Schwenn (2000) [34]	RCT	Germany	Healon5	20	—	—
	RCT	Germany	Viscoat	28	—	—
Stankovic (2008) [35]	RCT	Serbia	2% HPMC	20	—	—
	RCT	Serbia	Chondroitin sulfate 4%- NaHa 3%	20	—	—
Storr-Paulsen (2007) [36]	RCT	Denmark	Celoftal	17	77.9	8.1
	RCT	Denmark	Vitrax	16	76.6	10.4
	RCT	Denmark	Healon	19	76.4	13.1
Strobel (1997) [37]	RCT	Germany	Healon GV	30	68.9	10.8
	RCT	Germany	Healon	30	73.6	10.2
Thirumalai (2007) [38]	RCT	UK	Healon GV	415	—	—
Vajpayee (2005) [39]	RCT	India	Viscoat	19	69.6	9.2
	RCT	India	Healon GV	19	65.8	7.8
	RCT	India	Healon5	18	70.8	9.9
Yachimori (2004) [40]	RCT	Japan	Opegan	34	68.6	8.2
	RCT	Japan	Soft Shell	35	70.7	8.3